Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00163020 · ClinicalTrials.gov registry record · Phase 2
17OHP for Reduction of Neonatal Morbidity Due to Preterm Birth (PTB) in Twin and Triplet Pregnancies
A Phase 2 study, sponsored by Obstetrix Medical Group.
- Completed
- Registry status
- Phase 2
- Development phase
- 321
- Enrollment target
NCT00163020 is a Phase 2 study that has completed, run by Obstetrix Medical Group. The registered enrollment target is 321 participants.
The verdict
NCT00163020, a Phase 2 study, has completed, sponsored by Obstetrix Medical Group.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 321 participants
- Enrollment target
Study Summary
Hypothesis: Among women with twin or triplet pregnancies, weekly injections of 17-alpha-hydroxyprogesterone caproate (17OHP), started before 24 weeks of gestation, will reduce neonatal morbidity by reducing the rate of preterm delivery. This study involves two concurrent double-blinded randomized clinical trials of 17OHP versus placebo. Each trial will test the efficacy and safety of 17OHP in women with a specific risk factor for preterm birth. The two risk factors to be studied are: 1. Twin pregnancy 2. Triplet pregnancy
Interventions
- DRUG Placebo
- DRUG 17-alpha-hydroxyprogesterone caproate injectable
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 321 participants |
| Start Date | 2004-11 |
| Est. Completion | 2009-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00163020
The ClinicalTrials.gov registry entry for NCT00163020 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 321 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Obstetrix Medical Group, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00163020 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00163020 about?
NCT00163020 is a clinical study titled "17OHP for Reduction of Neonatal Morbidity Due to Preterm Birth (PTB) in Twin and Triplet Pregnancies". Hypothesis: Among women with twin or triplet pregnancies, weekly injections of 17-alpha-hydroxyprogesterone caproate (17OHP), started before 24 weeks of gestation, will reduce neonatal morbidity by reducing the rate of preterm delivery. This study involves two concurrent double-blinded randomized c...
What is the current status of trial NCT00163020?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 321 participants. The study started on 2004-11. Estimated completion is 2009-08.
What interventions are being tested in trial NCT00163020?
The interventions under investigation include: Placebo (DRUG), 17-alpha-hydroxyprogesterone caproate injectable (DRUG).
Who is sponsoring clinical trial NCT00163020?
This trial is sponsored by Obstetrix Medical Group, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.